The EPO published patent application EP4006043A1 for a carboplatin complex and pharmaceutical preparation thereof. The applicant is Advanchl Biotechnology Service Center based in Shanghai, China, with inventor ZHENG, Jianqiang. The IPC classifications indicate the compound is intended for pharmaceutical use, specifically for treating cancer (A61P 35/00), bacterial infections (A61P 31/04), and viral infections (A61P 31/20). The designated states cover most European Patent Convention member states including Germany, France, Italy, Spain, and the UK.

This is a patent publication notice with no immediate compliance requirements for third parties. Competitors developing similar platinum-based chemotherapy compounds should review freedom-to-operate implications. R&D teams may evaluate potential licensing opportunities. No action is required from compliance officers unless their organization is actively pursuing similar therapeutic indications in platinum-based oncology drugs.